HK1038879B - 利用氧化鎂穩定的含ace抑制劑的組合物 - Google Patents

利用氧化鎂穩定的含ace抑制劑的組合物

Info

Publication number
HK1038879B
HK1038879B HK02100407.5A HK02100407A HK1038879B HK 1038879 B HK1038879 B HK 1038879B HK 02100407 A HK02100407 A HK 02100407A HK 1038879 B HK1038879 B HK 1038879B
Authority
HK
Hong Kong
Prior art keywords
stabilization
magnesium oxide
compositions containing
ace inhibitors
containing ace
Prior art date
Application number
HK02100407.5A
Other languages
English (en)
Other versions
HK1038879A1 (en
Inventor
J‧E‧達尼爾
M‧R‧哈裏斯
G‧C‧霍肯森
J‧維斯
Original Assignee
沃尼爾‧朗伯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1038879(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 沃尼爾‧朗伯公司 filed Critical 沃尼爾‧朗伯公司
Publication of HK1038879A1 publication Critical patent/HK1038879A1/xx
Publication of HK1038879B publication Critical patent/HK1038879B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK02100407.5A 1998-06-05 2002-01-18 利用氧化鎂穩定的含ace抑制劑的組合物 HK1038879B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05
PCT/US1999/010189 WO1999062560A1 (en) 1998-06-05 1999-05-10 Stabilization of compositions containing ace inhibitors using magnesium oxide

Publications (2)

Publication Number Publication Date
HK1038879A1 HK1038879A1 (en) 2002-04-04
HK1038879B true HK1038879B (zh) 2004-10-08

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02100407.5A HK1038879B (zh) 1998-06-05 2002-01-18 利用氧化鎂穩定的含ace抑制劑的組合物

Country Status (32)

Country Link
US (3) US6417196B1 (zh)
EP (1) EP1083931B1 (zh)
JP (1) JP3727848B2 (zh)
KR (1) KR20010052557A (zh)
CN (1) CN1144598C (zh)
AR (1) AR019150A1 (zh)
AT (1) ATE295184T1 (zh)
AU (1) AU755616B2 (zh)
BR (1) BR9910947A (zh)
CA (1) CA2330581A1 (zh)
CO (1) CO5011043A1 (zh)
DE (1) DE69925269T2 (zh)
ES (1) ES2242398T3 (zh)
GT (1) GT199900079A (zh)
HK (1) HK1038879B (zh)
HN (1) HN1999000088A (zh)
HU (1) HUP0102260A3 (zh)
ID (1) ID27398A (zh)
IL (1) IL139590A0 (zh)
IS (1) IS2270B (zh)
MY (1) MY119667A (zh)
NO (1) NO20006148D0 (zh)
NZ (1) NZ508544A (zh)
PA (1) PA8475001A1 (zh)
PE (1) PE20000543A1 (zh)
PL (1) PL344586A1 (zh)
SV (1) SV1999000072A (zh)
TR (1) TR200003600T2 (zh)
TW (1) TW565455B (zh)
UY (1) UY25546A1 (zh)
WO (1) WO1999062560A1 (zh)
ZA (1) ZA200006537B (zh)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062560A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
KR100741937B1 (ko) * 2000-05-24 2007-07-24 오츠카 세이야쿠 가부시키가이샤 제제의 안정화 방법
ES2283774T3 (es) * 2002-01-15 2007-11-01 Actavis Group Hf. Formulaciones de quinapril e inhibidores de la eca relacionados.
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
MXPA06000226A (es) * 2003-06-26 2006-03-21 Teva Pharma Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo[3.3..0]-octano-3-carboxilico.
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US20060141054A1 (en) * 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
BRPI0710172A2 (pt) * 2006-04-19 2011-08-23 Teva Pharma composição farmacêutica estável de ácido carboxìlico derivado de 2-aza-biciclo[3,3,0]-octana-3
US20100035955A1 (en) * 2006-06-30 2010-02-11 Panagiotis Keramidas Stabilised Composition Comprising ACE Inhibitors
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
US8337817B2 (en) * 2006-12-26 2012-12-25 Shin Nippon Biomedical Laboratories, Ltd. Preparation for transnasal application
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
JP2012526726A (ja) * 2009-05-15 2012-11-01 株式会社新日本科学 薬物動態が改善された鼻腔内用薬学的組成物
US8827946B2 (en) 2009-07-31 2014-09-09 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) 1967-05-16 Method of preparing magnesia
IL58849A (en) 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
WO1999062560A1 (en) * 1998-06-05 1999-12-09 Warner-Lambert Company Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
IS2270B (is) 2007-07-15
TR200003600T2 (tr) 2001-04-20
AR019150A1 (es) 2001-12-26
JP3727848B2 (ja) 2005-12-21
BR9910947A (pt) 2001-03-06
CO5011043A1 (es) 2001-02-28
JP2002516881A (ja) 2002-06-11
GT199900079A (es) 2000-11-25
ES2242398T3 (es) 2005-11-01
CN1304322A (zh) 2001-07-18
EP1083931B1 (en) 2005-05-11
SV1999000072A (es) 2000-05-04
DE69925269D1 (de) 2005-06-16
TW565455B (en) 2003-12-11
WO1999062560A1 (en) 1999-12-09
ATE295184T1 (de) 2005-05-15
US6417196B1 (en) 2002-07-09
HUP0102260A2 (hu) 2002-03-28
NZ508544A (en) 2002-10-25
IS5712A (is) 2000-11-10
CN1144598C (zh) 2004-04-07
PE20000543A1 (es) 2000-08-10
UY25546A1 (es) 1999-09-27
ZA200006537B (en) 2001-11-12
PA8475001A1 (es) 2000-09-29
AU3979399A (en) 1999-12-20
MY119667A (en) 2005-06-30
DE69925269T2 (de) 2006-02-23
NO20006148L (no) 2000-12-04
HUP0102260A3 (en) 2002-12-28
ID27398A (id) 2001-04-05
US20060106057A1 (en) 2006-05-18
IL139590A0 (en) 2002-02-10
US20020161020A1 (en) 2002-10-31
EP1083931A1 (en) 2001-03-21
HN1999000088A (es) 2000-02-10
CA2330581A1 (en) 1999-12-09
NO20006148D0 (no) 2000-12-04
KR20010052557A (ko) 2001-06-25
HK1038879A1 (en) 2002-04-04
PL344586A1 (en) 2001-11-05
US7015232B2 (en) 2006-03-21
AU755616B2 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
HUP0102260A3 (en) Stabilization of compositions containing ace inhibitors using magnesium oxide
IL145778A0 (en) Methods and compositions for inhibiting the function of polynucleotide sequences
HK1039110A1 (zh) 以新穎的合成物及組分作為蛋白酶抑制劑
PL341372A1 (en) Cellecoxibe containing compositions
AU2002233929A1 (en) Compositions of peptide crystals
PL342113A1 (en) Sulphonamidic derivatives useful as precursors of aspartil protease inhibitors
PL345060A1 (en) Compounds of unstable dipeptidyl peptidase iv inhibitors
HUP0201011A2 (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors and pharmaceutical compositions containing them
IL137616A0 (en) Variants of vegf-a
AU5687199A (en) Use of anti-angiogenic agents for inhibiting vessel wall injury
IL141157A0 (en) Salt form of pantoprazole and pharmaceutical compositions containing the same
IL143071A0 (en) Dispersible compositions containing l-dopa ethyl ester
HUP0302160A3 (en) Pharmaceutical compositions containing the combination of gaba agonists and sorbitol dehydrogenase inhibitors
HUP0002951A3 (en) Bis-aminomethylcarbonyl compounds as protease inhibitors and pharmaceutical compositions containing them
HUP0103781A3 (en) Pharmaceutical compositions comprising atypical antiphsychotic agent in combination with acetylcholinesterase inhibitor for improving cognition
HUP0202255A3 (en) Crystalline 1-methylcarbapenem compounds and pharmaceutical compositions containing them
EP1069895A4 (en) COMPOSITIONS CONTAINING LYSOPHOSPHATIDE ACIDS THAT INHIBIT APOPTOSIS AND USES THEREOF
HUP0400654A3 (en) Substituted 8-arylquinoline phosphodiesterase 4 inhibitors and pharmaceutical compositions containing them
GB2353793B (en) Method of use of corrosion inhibitor compositions
EP1024812A4 (en) COMPOSITIONS CONTAINING LYSOPHOSPHATIDE ACIDS INHIBITING APOPTOSIS, AND USES THEREOF
HUP0200747A2 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
IL142534A0 (en) Pharmaceutical compositions containing an antigen-adjuvent
HUP0102363A3 (en) Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
AU2003287063A8 (en) Hemostatic and acid etch compositions containing sucralose
IL138601A0 (en) Pyrrolidines as inhibitors of neuraminidases

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080510